p21-senescent cells drive pancreatic islet dysfunction through targetable paracrine signaling in type 2 diabetes.
Level 5 - mechanism / opinion, no new human data
Preclinical laboratory and animal research utilizing human tissue samples and mouse models
PubMed 42262869 · doi:10.1172/jci.insight.197310
What was done
The authors evaluated the role of p21-expressing senescent pancreatic β cells in type 2 diabetes (T2D) using human and mouse islet models. They utilized spatial transcriptomics and proteomics to characterize this subpopulation, analyzed functional traits including glucose-stimulated insulin secretion and senescence-associated secretory phenotype (SASP) factor expression, and tested whether JAK inhibitors could block paracrine-induced secondary senescence and rescue β cell function in high-fat diet-fed mice and human T2D islets.
What was found
The abstract reports no quantitative values or effect sizes. Qualitatively, p21+ senescent β cells emerged early in T2D progression, showing loss of cellular identity, impaired glucose responsiveness, elevated basal insulin secretion, and secretion of SASP factors. These SASP factors induced secondary senescence and dysfunction in neighboring islet cells. Treatment with JAK inhibitors prevented secondary senescence and restored β cell function in both mouse models and human T2D islets.
Why it matters
This study delineates a paracrine mechanism by which a small population of senescent β cells impairs overall islet function in T2D, identifying JAK inhibition as a potential pharmacological target to preserve islet function.
Limits
The abstract provides no sample sizes, effect sizes, statistical measures, or donor characteristics. As a preclinical investigation combining in vitro, ex vivo human islet, and mouse experiments, the findings cannot establish in vivo human clinical efficacy or safety.
Cited by
- supports Senescent cells secrete signaling molecules and factors that cause damage to neighboring cells.